Table 1.
Baseline demographic characteristics—safety population
| Parameter | <65 years (n = 1915) | ≥65 years (n = 897) |
|---|---|---|
| Age (years) | ||
| Mean (SD) | 52.3 (8.5) | 71.9 (5.4) |
| Sex, n (%) | ||
| Female | 921 (48.1) | 434 (48.4) |
| Male | 994 (51.9) | 462 (51.5) |
| Missing | 0 | 1 (0.1) |
| Race, n (%) | ||
| White American | 1423 (74.3) | 732 (81.6) |
| Black or African American | 361 (18.9) | 130 (14.5) |
| Asian | 40 (2.1) | 9 (1.0) |
| American Indian or Alaska Native | 17 (0.9) | 10 (1.1) |
| Native Hawaiian or other Pacific Islander | 3 (0.2) | 1 (0.1) |
| Other | 50 (2.6) | 12 (1.3) |
| BMI (kg/m2), n (%) | 34.6 (6.3) | 32.4 (5.7) |
| Pre-trial insulin therapy, n (%) | ||
| Glargine | 684 (35.7) | 332 (37.0) |
| NPH | 98 (5.1) | 77 (8.6) |
| Insulin-naïvea | 697 (36.4) | 270 (30.1) |
| Others | 436 (22.8) | 218 (24.3) |
| A1C (%) | 8.65 | 8.22 |
| Fasting plasma glucose (mg/dL) | 180.5 | 160.2 |
| Body weight (kg) | 101.2 | 91.8 |
| Duration of type 2 diabetes | ||
| n | 1909 | 897 |
| y, SD | 9.8 (7.3) | 14.3 (9.1) |
BMI body mass index, NPH neutral protamine Hagedorn, SD standard deviation
aInsulin-naïve is defined as patients who took oral anti-diabetes drugs only or did not have therapy as pretreatment